<b>Liver Biomarkers And Treatments Data</b>

This dataset appears to focus on liver health, metabolic markers, and the effects of different medications. It includes a mix of demographic, clinical, biochemical, and histopathological data points. Below is a detailed breakdown:<b>Demographic Information:</b><b>Gender:</b> Gender of the individual (e.g., 0 for male, 1 for female or vice versa).<b>Age:</b> Age of the individual in years.<b>Medication Usage:</b><b>Statin_Usage:</b> Indicates whether statins are being used (0 = no, 1 = yes).<b>Ezetimibe_Usage:</b> Indicates usage of ezetimibe (0 = no, 1 = yes).<b>Fibrate_Usage:</b> Indicates usage of fibrates (0 = no, 1 = yes).<b>EPA_Usage:</b> Indicates usage of EPA (0 = no, 1 = yes).<b>Biochemical Markers:</b><b>GPT:</b> Levels of glutamate pyruvate transaminase (GPT), a liver enzyme.<b>Gamma-GTP:</b> Levels of gamma-glutamyl transferase (GGT), another liver enzyme.<b>Triglycerides_Serum:</b> Serum triglyceride levels.<b>Lp(a)_mg_dL:</b> Lipoprotein(a) levels measured in mg/dL.<b>Histopathological Findings:</b><b>Lobular_Inflammation_1, Lobular_Inflammation_2, Lobular_Inflammation_3:</b> Severity levels of lobular inflammation.<b>Ballooning_1, Ballooning_2:</b> Levels of hepatocyte ballooning, indicative of cellular damage.<b>Steatosis_2, Steatosis_3:</b> Levels of steatosis, representing fat accumulation in the liver.<b>Groups and Conditions:</b><b>Group_Statin+Ezetimibe:</b> Group classification based on combined statin and ezetimibe usage.<b>LiverStage_1, LiverStage_2:</b> Categorical liver disease stages (e.g., 1 for early stage, 2 for advanced stage).